The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
Abstract
BACKGROUND: Current antihumoral therapies in transplantation and autoimmune disease do not target the mature antibody-producing plasma cell. Bortezomib is a first in class proteosomal inhibitor, that is Food and Drug Administration approved, for the treatment of plasma cell-derived tumors that is multiple myeloma. We report the first clinical experience with plasma cell-targeted therapy (bortezomib) as an antirejection strategy. METHODS: Eight episodes of mixed antibody-mediated rejection (AMR) and acute cellular rejection (ACR) in six transplant recipients were treated with bortezomib at labeled dosing. Monitoring included serial donor-specific antihuman leukocyte antigen antibody (DSA) levels and repeated allograft biopsies. RESULTS: Six kidney transplant patients received bortezomib for AMR and concomitant ACR. In each case, bortezomib therapy provided (1) prompt rejection reversal, (2) marked and prolonged reductions in DSA levels, (3) improved renal allograft function, and (4) suppression of recurrent rejection for at least 5 months. Moreover, immunodominant DSA (iDSA) (i.e., the antidonor human leukocyte antigen antibody with the highest levels) levels were decreased by more than 50% within 14 days and remained substantially suppressed for up to 5 months. One or more additional DSA were present at lower concentrations (non-iDSA) in each patient and were also reduced to nondetectable levels. Bortezomib-related toxicities (gastrointestinal toxicity, thrombocytopenia, and paresthesias) were all transient. CONCLUSIONS: Bortezomib therapy: (1) provides effective treatment of AMR and ACR with minimal toxicity and (2) provides sustained reduction in iDSA and non-iDSA levels. Bortezomib represents the first effective antihumoral therapy with activity in humans that targets plasma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Solez, K., Colvin, R., Racusen, L., Sis, B., Halloran, P., Birk, P., Campbell, P., Cascalho, M., Collins, A., Demetris, A., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01688.x · Cited by 1,082
Racusen, L. C., Colvin, R. B., Solez, K., Mihatsch, M. J., Halloran, P. F., Campbell, P. M., Cecka, M. J., Cosyns, J., Demetris, A. J., Fishbein, M. C., et al. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00072.x · Cited by 1,060
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05188.x · Cited by 740
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis
Palombella, V. J., Conner, E. M., Fuseler, J. W., Destree, A., Davis, J. M., Laroux, F. S., Wolf, R. E., Huang, J., Brand, S., Elliott, P. J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15671 · Cited by 287
Cited by
Tait, B. D., Süsal, C., Gebel, H. M., Nickerson, P. W., Zachary, A. A., Claas, F. H. J., Reed, E. F., Bray, R. A., Campbell, P., Chapman, J. R., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e31827a19cc · Cited by 787
Colvin, M. M., Cook, J. L., Chang, P., Francis, G., Hsu, D. T., Kiernan, M. S., Kobashigawa, J. A., Lindenfeld, J., Masri, S. C., Miller, D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000093 · Cited by 376
Alexander, T., Sarfert, R., Klotsche, J., Kühl, A. A., Rubbert-Roth, A., Lorenz, H.-M., Rech, J., Hoyer, B. F., Cheng, Q., Waka, A., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206016 · Cited by 368
Report from a consensus conference on antibody-mediated rejection in heart transplantation
Kobashigawa, J., Crespo-Leiro, M. G., Ensminger, S. M., Reichenspurner, H., Angelini, A., Berry, G., Burke, M., Czer, L., Hiemann, N., Kfoury, A. G., et al. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.11.003 · Cited by 368
Antibody-mediated vascular rejection of kidney allografts: a population-based study
Lefaucheur, C., Loupy, A., Vernerey, D., Duong-Van-Huyen, J.-P., Suberbielle, C., Anglicheau, D., Vérine, J., Beuscart, T., Nochy, D., Bruneval, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61265-3 · Cited by 340
Metadata
- Authors
- Everly, M. J., Everly, J. J., Susskind, B., Brailey, P., Arend, L. J., Alloway, R. R., Roy-Chaudhury, P., Govil, A., Mogilishetty, G., Rike, A. H., Cardi, M., Wadih, G., Tevar, A., & Woodle, E. S.
- Venue
- Transplantation
- Published
- 2008-12-27
- Volume
- 86
- Issue
- 12
- Pages
- 1754-1761
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1989569525
- Cited by
- 392
- References
- 21
- FWCI
- 28.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection. https://app.cochat.ai/papers/10.1097/tp.0b013e318190af83
- The paper
- Everly, M. J., Everly, J. J., Susskind, B., Brailey, P., Arend, L. J., Alloway, R. R., Roy-Chaudhury, P., Govil, A., Mogilishetty, G., Rike, A. H., Cardi, M., Wadih, G., Tevar, A., & Woodle, E. S. (2008). Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection. Transplantation. https://doi.org/10.1097/tp.0b013e318190af83
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.